Smart Immune et CELLforCURE by SEQENS s'associent pour industrialiser la production des lots cliniques de SMART101
03 déc. 2024 00h00 HE
|
Smart Immune
COMMUNIQUÉ DE PRESSE | Paris, France - 3 décembre 2024 Smart Immune, société de biotechnologie en stade clinique, et CELLforCURE by SEQENS, entreprise de développement et de fabrication en...
Smart Immune and CELLforCURE by SEQENS Partner to Industrialize SMART101 Clinical Batches Manufacturing
03 déc. 2024 00h00 HE
|
Smart Immune
PRESS RELEASE | Paris, France – December 3, 2024 Smart Immune, a clinical-stage biotechnology company, and CELLforCURE by SEQENS, a Contract Development and Manufacturing Organization (CDMO) for...
CAR T-cell Therapy Strategic Business Research Report 2024: Global Market to Reach $10.8 Billion by 2030 - Expanding Clinical Applications Beyond Blood Cancers Expands Opportunities
02 déc. 2024 06h31 HE
|
Research and Markets
Dublin, Dec. 02, 2024 (GLOBE NEWSWIRE) -- The "CAR T-cell Therapy - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.The global market for CAR T-cell...
Cell and Gene Therapy Tools and Reagents Market Report 2024 - Driving Medical Advances: Cell and Gene Therapy Tools Market to Hit $16.7 Billion by 2029
29 nov. 2024 04h24 HE
|
Research and Markets
Dublin, Nov. 29, 2024 (GLOBE NEWSWIRE) -- The "Cell and Gene Therapy Tools and Reagents Market" report has been added to ResearchAndMarkets.com's offering.The Cell and Gene Therapy Tools and...
Immatics Announces Third Quarter 2024 Financial Results, Business Update and First Clinical Data on TCER® IMA402 Targeting PRAME
18 nov. 2024 07h00 HE
|
https://immatics.com/
The Company will now target five major cancer types with its four clinically active compounds across both TCR-T cell therapies and TCR-based Bispecifics Today, Company discloses first clinical...
Quell Therapeutics Achieves Milestone for Type 1 Diabetes CAR-Treg Cell Therapy Program
18 nov. 2024 04h00 HE
|
Quell TX
Achievement of first significant research milestone triggers an option exercise payment of $10 million from AstraZenecaAstraZeneca will progress preclinical and clinical development of the selected...
Turnstone Biologics Corp. Reports Third Quarter 2024 Financial Results and Provides Recent Business Highlights
12 nov. 2024 16h05 HE
|
Turnstone Biologics Corp.
Turnstone reports third quarter 2024 financial results and provides recent business highlights
Cherry T. Thomas, M.D., Joins Wugen as Chief Medical Officer, Bringing Cell Therapy Expertise Across Clinical Development, Regulatory, and Medical Affairs as the Company Embarks on a Pivotal Trial for its Investigational, Allogeneic CD7-Targeted CAR-T Cell Therapy
12 nov. 2024 07h05 HE
|
Wugen
Cherry T. Thomas, M.D., Joins Wugen as Chief Medical Officer, Bringing Cell Therapy Expertise Across Clinical Development, Regulatory, and Medical Affairs
Wugen to Initiate a Pivotal Trial for Its Investigational, Off-the-Shelf, Allogeneic, CD7-Targeted CAR-T Cell Therapy, WU-CART-007, in Patients with Relapsed or Refractory T Cell Acute Lymphoblastic Leukemia or T Cell Lymphoblastic Lymphoma
12 nov. 2024 07h00 HE
|
Wugen
Wugen to Initiate a Pivotal Trial for Its Investigational, Off-the-Shelf, Allogeneic, CD7-Targeted CAR-T Cell Therapy, WU-CART-007
Immatics Announces Multiple Presentations at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) on TCR-T Therapy Candidates Targeting PRAME
08 nov. 2024 17h00 HE
|
https://immatics.com/
Two oral presentations and multiple posters on clinical andpreclinical-stage candidates to be presented at SITC, demonstratingthe strength of Immatics’ TCR-T PRAME franchise to target solid cancers ...